We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Head and Neck Cancer: Mutant HRAS Is a Key Cancer-Driving Oncogene

News   Aug 03, 2020 | Original story from UC San Diego

 
Head and Neck Cancer: Mutant <i>HRAS</i> Is a Key Cancer-Driving Oncogene
 
 
Advertisement
 

RELATED ARTICLES

Algorithms Uncover Cancers’ Unseen Genetic Losses and Gains

News

Scientists have created new mathematical tools that allow scientists to search the vast collection of DNA snippets and uncover whether there are either missing pieces or duplicates. These algorithms, dubbed HATCHet and CHISEL, could help to improve diagnosis and treatment.

READ MORE

A Look at How Psychedelics Bind to Serotonin Receptors

News

For the first time, scientists have solved the high-resolution structure of psychedelic compounds when they are actively bound to the 5-HT2A serotonin receptor on the surface of brain cells.

READ MORE

Phase 3 Clinical Trial of Belimumab for Lupus Nephritis Reports Positive Results

News

Results from the largest Phase 3 lupus nephritis clinical trial ever conducted were announced, September 16. The study, found positive results of the efficacy and safety of the drug belimumab in patients with active lupus nephritis, a condition that causes inflammation in the kidneys of patients with systemic lupus erythematosus.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE